Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.
The U.S. Food and Drug Administration rejected Orphazyme’s key drug candidate for Niemann-Pick disease type C (NPC), causing the Denmark-based biopharmaceutical company’s “meme stock” to decline in trading.
The U.S. Food and Drug Administration accepted Copenhagen, Denmark-based Orphazyme’s New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick disease Type C.
Mallinckrodt plc will acquire Sucampo Pharmaceuticals Inc., including its commercial and development assets.
Rockville, Md.-based Sucampo Pharmaceuticals has acquired privately held Gaithersburg, Md.-based Vtesse.
BioSpace (DHX) is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States. Once BioSpace sorted the companies into that group, they were then weighted by a number of different categories and ranked in a cumulative […]